Revolution Medicines (RVMD) Other Non-Current Liabilities (2019 - 2026)

Revolution Medicines has reported Other Non-Current Liabilities for 8 years, with the latest figure at $6.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 817.2% year-over-year to $6.9 million; the trailing twelve-month figure through Mar 2026 stood at $6.9 million (up 817.2% YoY), and the FY2025 full-year result was $1.2 million, down 62.12% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $6.9 million, up from $1.2 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $7.2 million in Q2 2025, with the low at $219000.0 in Q2 2022.
• Average Other Non-Current Liabilities over 5 years is $2.3 million, with a median of $1.5 million recorded in 2023.
• Year-over-year, Other Non-Current Liabilities plunged 76.24% in 2025 and jumped 817.2% in 2026.
• Tracing RVMD's Other Non-Current Liabilities over 5 years: stood at $301000.0 in 2022, then soared by 384.39% to $1.5 million in 2023, then soared by 118.72% to $3.2 million in 2024, then tumbled by 62.12% to $1.2 million in 2025, then jumped by 469.45% to $6.9 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $6.9 million (Q1 2026), $1.2 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.

Peer Comparison